James Cullem is a life sciences executive and serial entrepreneur with more than 20 years of experience in the development, growth and management of early-stage businesses. He currently leads Paradigm Oncology as chief executive officer and co-founder. Cullem is the former co-founder and CEO of Halcyon Diagnostics and has expertise in the proteomics, genomics, cancer diagnostics, and personalized medicine sectors.
Before his tenure with Paradigm Oncology, James Cullem led the intellectual property, licensing, and corporate development activities at Enzymatics, Inc. in Beverly, Massachusetts. He has been a well-known leader in consulting and technology firms, serving with esteemed organizations such as Chiron Corporation (now Novartis Diagnostics) and Cell Signaling Technology, Inc.
In 2007, James Cullem founded strategic intellectual property consulting firm Aurora Nova, LLC. There, he supported numerous life-sciences organizations in the areas of business strategy development, intellectual property, executive management, intellectual property management and corporate development.
James Cullem is a graduate of Franklin Pierce Law Center (J.D., 1999) and University of California – Davis (B.S. Biochemistry, 1990). For the former institution, he shares the gift of learning with today’s students by serving on the Intellectual Property Advisory Committee. James Cullem is a former co-chair of BPLA (Boston Patent Law Association).
James Cullem is a member of the Association of Corporate Counsel (ACC), the American Intellectual Property Law Association (AIPLA) and the Licensing Executives Society (LES). He has regularly offered guidance and insight as a guest speaker on patent practice, license and intellectual property management at various industry conferences. A published author, James Cullem has been featured prominently in the Journal of Commercial Biotechnology.